Overcoming MCL-1-driven adaptive resistance to targeted therapies

Two complementary studies in Nature Communications define a critical role for the anti-apoptotic protein MCL-1 as a driver of adaptive survival in tumor cells treated with oncogene targeted therapies, providing a rationale for combining these agents with newly developed MCL-1 inhibitors in the clini...

Descripción completa

Detalles Bibliográficos
Autor principal: Wood, Kris C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985132/
https://www.ncbi.nlm.nih.gov/pubmed/31988312
http://dx.doi.org/10.1038/s41467-020-14392-z
_version_ 1783491756180897792
author Wood, Kris C.
author_facet Wood, Kris C.
author_sort Wood, Kris C.
collection PubMed
description Two complementary studies in Nature Communications define a critical role for the anti-apoptotic protein MCL-1 as a driver of adaptive survival in tumor cells treated with oncogene targeted therapies, providing a rationale for combining these agents with newly developed MCL-1 inhibitors in the clinic.
format Online
Article
Text
id pubmed-6985132
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-69851322020-01-29 Overcoming MCL-1-driven adaptive resistance to targeted therapies Wood, Kris C. Nat Commun Comment Two complementary studies in Nature Communications define a critical role for the anti-apoptotic protein MCL-1 as a driver of adaptive survival in tumor cells treated with oncogene targeted therapies, providing a rationale for combining these agents with newly developed MCL-1 inhibitors in the clinic. Nature Publishing Group UK 2020-01-27 /pmc/articles/PMC6985132/ /pubmed/31988312 http://dx.doi.org/10.1038/s41467-020-14392-z Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Comment
Wood, Kris C.
Overcoming MCL-1-driven adaptive resistance to targeted therapies
title Overcoming MCL-1-driven adaptive resistance to targeted therapies
title_full Overcoming MCL-1-driven adaptive resistance to targeted therapies
title_fullStr Overcoming MCL-1-driven adaptive resistance to targeted therapies
title_full_unstemmed Overcoming MCL-1-driven adaptive resistance to targeted therapies
title_short Overcoming MCL-1-driven adaptive resistance to targeted therapies
title_sort overcoming mcl-1-driven adaptive resistance to targeted therapies
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985132/
https://www.ncbi.nlm.nih.gov/pubmed/31988312
http://dx.doi.org/10.1038/s41467-020-14392-z
work_keys_str_mv AT woodkrisc overcomingmcl1drivenadaptiveresistancetotargetedtherapies

Ejemplares similares